Biontech SE- 详细介绍、公司背景、业务范围、财务数据以及市场表现

关于公司

公司简介

公司代码BNTX

公司名称Biontech SE

上市日期Oct 10, 2019

CEOProf. Ugur Sahin, M.D.

员工数量6772

证券类型Depository Receipt

年结日Oct 10

公司地址An der Goldgrube 12

城市MAINZ

上市交易所NASDAQ Global Select Consolidated

国家Germany

邮编55131

电话4949613190840

网址https://www.biontech.com/

公司代码BNTX

上市日期Oct 10, 2019

CEOProf. Ugur Sahin, M.D.

公司高管

名称

名称/职务

职务

持股

持股变动

Dr. Sierk Poetting, Ph.D.

Chief Operating Officer, Member of the Management Board

767.54K

+1.69%

Mr. Ryan Richardson

Chief Strategy Officer, Member of the Management Board

26.55K

+80.66%

Dr. Ulrich Wandschneider, Ph.D.

Independent Deputy Chairman of the Supervisory Board

1.48K

--

Mr. James Ryan

Member of the Management Board, Chief Legal Officer

790.00

--

Prof. Rudolf Staudigl, Ph.D.

Independent Member of the Supervisory Board

400.00

--

Prof. Anja Morawietz, Ph.D.

Independent Member of the Supervisory Board

240.00

--

Mr. Ramon Zapata Gomez

Chief Financial Officer

--

Mr. Helmut Jeggle

Independent Chairman of the Supervisory Board

--

Dr. Oezlem Tuereci, M.D.

Chief Medical Office, Member of the Management Board

--

Ms. Baroness Nicola Blackwood

Member of the Supervisory Board

--

名称

名称/职务

职务

持股

持股变动

Dr. Sierk Poetting, Ph.D.

Chief Operating Officer, Member of the Management Board

767.54K

+1.69%

Mr. Ryan Richardson

Chief Strategy Officer, Member of the Management Board

26.55K

+80.66%

Dr. Ulrich Wandschneider, Ph.D.

Independent Deputy Chairman of the Supervisory Board

1.48K

--

Mr. James Ryan

Member of the Management Board, Chief Legal Officer

790.00

--

Prof. Rudolf Staudigl, Ph.D.

Independent Member of the Supervisory Board

400.00

--

Prof. Anja Morawietz, Ph.D.

Independent Member of the Supervisory Board

240.00

--

收入明细

单位: USD更新时间: 3月12日周三

FY2019

FY2018

FY2017

业务USD

名称

营收

占比

Collaboration Revenue

84.43M

77.75%

Revenues from Other Sales Transactions

24.16M

22.25%

暂无数据

业务

地区

业务USD

名称

营收

占比

Collaboration Revenue

84.43M

77.75%

Revenues from Other Sales Transactions

24.16M

22.25%

股东统计

更新时间: 8月17日周日

持股股东

股东类型

持股股东

占比

AT Impf GmbH

42.37%

Medine GmbH

16.69%

Baillie Gifford & Co.

3.34%

Fidelity Management & Research Company LLC

2.90%

Flossbach von Storch AG

1.76%

其他

32.93%

持股股东

占比

AT Impf GmbH

42.37%

Medine GmbH

16.69%

Baillie Gifford & Co.

3.34%

Fidelity Management & Research Company LLC

2.90%

Flossbach von Storch AG

1.76%

其他

32.93%

股东类型

持股股东

占比

Corporation

60.58%

Investment Advisor

16.91%

Investment Advisor/Hedge Fund

3.59%

Individual Investor

2.11%

Research Firm

1.00%

Hedge Fund

0.83%

Sovereign Wealth Fund

0.63%

Bank and Trust

0.22%

Pension Fund

0.19%

其他

13.94%

机构持股

更新时间: 7月1日周二

报告期

机构数

持股数

持股占比

持股变动

2025Q2

815

205.26M

85.38%

-4.32M

2025Q1

851

205.71M

85.57%

-4.55M

2024Q4

869

205.33M

85.56%

+3.19M

2024Q3

843

197.46M

82.52%

-2.61M

2024Q2

819

194.42M

81.78%

-7.50M

2024Q1

835

193.57M

81.42%

-10.02M

2023Q4

897

193.24M

81.29%

-7.90M

2023Q3

920

192.71M

79.62%

-7.47M

2023Q2

940

195.49M

80.61%

-8.54M

2023Q1

953

197.88M

81.52%

-6.52M

股东持股明细

名称

持股数

占比

持股变动

变动比例

公告日期

AT Impf GmbH

101.85M

42.37%

-636.54K

-0.62%

Dec 31, 2024

Medine GmbH

40.13M

16.69%

-304.48K

-0.75%

Mar 31, 2025

Baillie Gifford & Co.

8.16M

3.39%

-60.90K

-0.74%

Mar 31, 2025

Fidelity Management & Research Company LLC

5.95M

2.48%

-495.85K

-7.69%

Mar 31, 2025

Flossbach von Storch AG

4.26M

1.77%

-147.21K

-3.34%

Mar 31, 2025

PRIMECAP Management Company

4.05M

1.68%

-249.39K

-5.81%

Mar 31, 2025

Pfizer Inc

3.66M

1.52%

--

Mar 31, 2025

Sahin (Ugur MD)

2.05M

0.85%

-724.50K

-26.11%

Mar 31, 2025

Temasek Holdings Pte. Ltd.

1.81M

0.75%

--

Mar 31, 2025

持股ETF

更新时间: 9月6日周六

机构名称

占比

iShares Genomics Immunology and Healthcare ETF

3.71%

Global X Genomics & Biotechnology ETF

3.6%

Langar Global HealthTech ETF

3.46%

First Trust NYSE Arca Biotechnology Index Fund

2.97%

Franklin Genomic Advancements ETF

2.68%

VanEck Biotech ETF

2.65%

WisdomTree BioRevolution Fund

1.8%

Virtus LifeSci Biotech Products ETF

1.74%

iShares Biotechnology ETF

1.44%

ProShares Ultra Nasdaq Biotechnology

1.15%

iShares Genomics Immunology and Healthcare ETF

占比3.71%

Global X Genomics & Biotechnology ETF

占比3.6%

Langar Global HealthTech ETF

占比3.46%

First Trust NYSE Arca Biotechnology Index Fund

占比2.97%

Franklin Genomic Advancements ETF

占比2.68%

VanEck Biotech ETF

占比2.65%

WisdomTree BioRevolution Fund

占比1.8%

Virtus LifeSci Biotech Products ETF

占比1.74%

iShares Biotechnology ETF

占比1.44%

ProShares Ultra Nasdaq Biotechnology

占比1.15%

分红派息

近5年累计派现 0.00 美元

公告日期

分红计划

股权登记日

现金发放日

除权除息日

暂无数据

拆合股

公告日期

类型

比率

暂无数据

公告日期

类型

比率

暂无数据

Biontech SE

98.080USD

Biontech SE

98.080

概览

公司

财务

分析